Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-04-26
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1091
- Registration Number
- NCT00318461
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sunbury on Thames, United Kingdom
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-04-26
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1041
- Registration Number
- NCT00318422
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Izmir, Turkey
The Effect of Exercise on Blood Glucose Levels in Patients With Type 1 Diabetes: A Comparison of 3 Long-acting Insulins
Phase 4
Completed
- Conditions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 51
- Registration Number
- NCT00313742
Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-04-11
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 373
- Registration Number
- NCT00313001
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Plainsboro, New Jersey, United States
Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-04-07
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 325
- Registration Number
- NCT00312104
- Locations
- 🇿🇦
Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa
Comparison of Efficacy and Safety of Insulin Detemir and NPH Insulin in Children and Adolescents With Type 1 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-04-07
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 347
- Registration Number
- NCT00312156
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Stirling, United Kingdom
To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2006-02-22
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 746
- Registration Number
- NCT00294723
- Locations
- 🇵🇷
Novo Nordisk Investigational Site, Rio Piedras, Puerto Rico
Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-01-30
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 583
- Registration Number
- NCT00283751
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom
Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes
Phase 4
Completed
- Conditions
- First Posted Date
- 2006-01-26
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 79
- Registration Number
- NCT00282451
- Locations
- 🇸🇦
Novo Nordisk Investigational Site, Riyadh, Saudi Arabia
Effect of Biphasic Insulin Aspart 30 on Blood Glucose Control in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-01-20
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 307
- Registration Number
- NCT00280046
- Locations
- 🇷🇺
Novo Nordisk Investigational Site, Voronezh, Russian Federation
© Copyright 2024. All Rights Reserved by MedPath